# Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01572792** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 921 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
- **DRUG:** Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
- **DRUG:** Aclidinium bromide
- **DRUG:** Formoterol Fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01572792
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 921 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572792, "Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01572792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*